Please login to the form below

Not currently logged in
Email:
Password:

Sanofi pasteur launches new €100m vaccine plant

Sanofi Pasteur has opened a new €100m vaccination production plant in France capable of rapid turned around to make immunisation drugs in the event of an influenza pandemic
Sanofi Pasteur has opened a new €100m vaccination production plant in France capable of rapid turned around to make immunisation drugs in the event of an influenza pandemic.

The company, which is a division of sanofi-aventis, says its inaugural production site in Val de Reuil is equipped with state-of-the-art automated technology and is designed to cope with the rising demand for vaccination medicines. Should the World Health Organisation (WHO) identify a pandemic of influenza, Sanofi Pasteur claims that the facility can be turned around to produce enough vaccines to meet the requirements of such an occurrence.

Wayne Pisano, president and CEO of Sanofi Pasteur, who opened the French production plant, said that the demand for vaccines will double by the year 2016.

"Sanofi Pasteur's commitment to global health is exemplified by significant investments in vaccine production infrastructures," he said.

"The new facility will provide a high-end production work environment for dedicated people who produce vaccines for the world."

Funding for this new site is set to boost the level of production to 200 million syringes filled and shipped ever year, a significant increase from the current level of two million vaccines per annum.

A further €100m is being spent on constructing a building in Val de Reuil for the formulation of vaccines. This forms part of a larger €600m investment programme initiated by the company in 2005. Pisano is confident that the new facilities will help the firm provide the global healthcare community with high quality vaccinations.

26th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics